Patents by Inventor Erik Krogh-Jespersen

Erik Krogh-Jespersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Morphinan derivatives for the treatment of neuropathic pain
    Patent number: 10766864
    Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 8, 2020
    Assignee: Nektar Therapeutics
    Inventors: Neel K. Anand, Natalia Aurrecoechea, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, YongQi Mu, Erik Krogh-Jespersen
  • MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN
    Publication number: 20180127375
    Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 10, 2018
    Inventors: Neel K. Anand, Natalia Aurrecoechea, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, YongQi Mu, Erik Krogh-Jespersen
  • N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9512111
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 6, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur G. Romero, Chad A. Van Huis, Thomas D. Aicher, Carl Kaub, Matthew N. Mattson, William D. Thomas, Karin A. Stein, Erik Krogh-Jespersen, Zhan Wang
  • N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20140088094
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Application
    Filed: November 8, 2011
    Publication date: March 27, 2014
    Applicants: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur Glenn Romero, Chad A. Van Huis, Thomas Daniel Aicher, Carl Kaub, Matthew N. Mattson, William David Thomas, Karin Ann Sttein, Erik Krogh-Jespersen, Zhan Wang